Nuclear Pore Protein p62 Autoantibodies in Systemic Lupus Erythematosus

Doris M Kraemer*, 1, Hans-Peter Tony2
1 Queen’s Cancer Centre, Hull, UK
2 Medizinische Klinik and Poliklinik II, University of Wuerzburg, Germany

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2464
Abstract HTML Views: 1674
PDF Downloads: 494
Total Views/Downloads: 4638
Unique Statistics:

Full-Text HTML Views: 1242
Abstract HTML Views: 1082
PDF Downloads: 371
Total Views/Downloads: 2700

Creative Commons License
© Kraemer and Tony; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Haematology Department, Queen Cancer Centre of Oncology and Haematology, Castle Road, Cottingham, HU16 5JQ, UK; Tel: (44) 01482 461291; Fax: (44) 01482 607739; E-mail:


Systemic lupus erythematosus (SLE) is a systemic autoimmune disease which is classically characterised by a variety of autoantibodies to deoxyribonucleic acid (DNA), ribonucleic acid (RNA), other nuclear and cytoplasmic antigens. Recently several novel autoantibodies against a variety of specific nuclear pore proteins have been described, including the nucleoporin p62. In this paper we evaluate anti-nucleoporin p62 antibodies by western blot analysis in 25 systemic lupus erythematosus patients. Six patients showed antibodies directed against nucleoporin p62. Our data indicate that p62 antibodies could be a useful additional marker in SLE.

Keywords: Systemic lupus erythematosus, autoantibodies, nucleoporin p62..